Abstract 568P
Background
Osimertinib (osi), a third-generation, CNS-active EGFR-TKI, is the preferred 1L treatment for EGFRm advanced NSCLC, based on significant clinical benefit in the FLAURA study; however, most patients (pts) will develop disease progression. FLAURA2 (NCT04035486) is a global, phase III, open-label, randomised study of 1L osi + platinum-pemetrexed (pem) vs osi monotherapy in EGFRm advanced NSCLC. The FLAURA2 SRI phase assessed the safety/tolerability of the combination prior to the randomised period. We report final data following 3-years additional follow-up (previous data cut-off [DCO]: 19 Feb 2020).
Methods
Overall, 30 pts (≥18 years; ≥20 years Japan) with locally advanced/metastatic NSCLC received oral osi 80 mg once daily (QD) + either intravenous cisplatin 75 mg/m2 or carboplatin AUC5 + pem 500 mg/m2 every 3 weeks (Q3W) for 4 cycles, then maintenance osi (80 mg QD) + pem 500 mg/m2 (Q3W) until progression/discontinuation. SRI primary endpoint: safety; secondary endpoints: ORR, DCR, duration/depth of response and OS. DCO: 03 Apr 2023.
Results
Median age (range): 61 (45–84) years; 63% female; 73% Asian, 37% former smoker. Median exposure (range): 38.6 (1.9–44.6) months osi / 15.0 (1.0–64.0) cycles pem; 47% ongoing osi and 17% ongoing pem at DCO; 80% completed 4 cycles carbo/cis-platin. With 3 further years’ exposure, 2 more pts had adverse events (AEs) (n=29 [97%] total), 5 more had serious AEs (n=11 [37%] total), 4 more had Grade ≥3 AEs (n=15 [50%] total) and 1 new AE leading to death (n=2 [7%] total). No new cases of ILD/pneumonitis reported. New Grade ≥3 AEs included COVID-19/pneumonia (n=1 each). New AEs leading to discontinuation: 4 pem (n=10 [33%] total); none osi. No new safety signals were observed. Clinical benefit was observed (Table).
Conclusions
Osi + platinum-pem was well tolerated and clinical benefit continued with 3 further years’ exposure. Data support long-term tolerability of 1L osi + platinum-pem for EGFRm advanced NSCLC. Table: 568P
Efficacy endpoint | Osimertinib + carboplatin/cisplatin + pemetrexed (N=30) |
Confirmed ORR, n (%) (95% CI)Complete responsePartial response | 26 (87) (69.3–96.2)3 (10)23 (77) |
Non-response, n (%)Stable disease ≥35 days | 4 (13) |
Median duration of response, months (range) | 34.0 (2.0–43.0) |
Best percentage change from baseline in target lesion size, median % (range) | -59.6 (-100.0 – -6.4) |
DCR, n (%) (95% CI) | 30 (100) (88.4–100.0) |
Median OS, months (95% CI)2 year OS, % (95% CI)3 year OS, % (95% CI) | NR (34.0–NC)90 (72.1–96.7)69 (48.9–82.6) |
Median PFS, months (95% CI)2 year PFS, % (95% CI)3 year PFS, % (95% CI) | NR (25.6–NC)76 (55.9–87.7)55 (35.6–71.0) |
CI, confidence interval; NC, not calculable; NR, not reached
Clinical trial identification
NCT04035486.
Editorial acknowledgement
The authors would like to acknowledge Gemma White, MSc, of Ashfield MedComms, an Inizio Company, for medical writing support in accordance with Good Publications Practice (GPP) guidelines (https://www.ismpp.org/gpp-2022).
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
D. Planchard: Financial Interests, Personal, Advisory Board: AstraZeneca, AbbVie, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Merck, Novartis, Janssen, Pfizer, Roche, Pierre-fabre, Takeda, ArriVent, Mirati, Seagen; Non-Financial Interests, Institutional, Coordinating PI: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmune, Sanofi-Aventis, Taiho Pharma, Novocure, Daiichi Sankyo, AbbVie, Janssen, Pierre Fabre, Takeda, ArriVent, Mirati, Seagen; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Janssen, Pfizer, Roche, Pierre Fabre, Takeda, ArriVent, Mirati, Seagen. S. Kim: Non-Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Boehringer Ingelheim, Janssen, Norvasc, Takeda, Terrapex, Yuhan; Non-Financial Interests, Personal, Funding: Yuhan; Non-Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim. T.M. Kim: Non-Financial Interests, Personal, Advisory Board: Boryung, Janssen, Novartis, Takeda, Regeneron; Financial Interests, Personal, Advisory Role: AstraZeneca, Boryung, Hanmi, IMBDx, Janssen, Novartis, Takeda, Sanofi, Regeneron, Roche/Genentech, Samsung Bioepis; Non-Financial Interests, Personal, Coordinating PI: Regeneron; Financial Interests, Institutional, Local PI: ABBVIE, AstraZeneca, Bayer, Black Diamond Therapeutics, Blueprint Medicines, Boryung, Bristol Myers Squibb, Celgene, F. Hoffmann-La Roche Ltd/Genentech, Inc, Hanmi, Janssen, Novartis, Regeneron, Sanofi, Takeda, and Yuhan. N. Yanagitani: Non-Financial Interests, Personal, Advisory Board: Pfizer Inc.; Non-Financial Interests, Personal, Speaker, Consultant, Advisor, Consultant: Chugai; Financial Interests, Personal, Speaker, Consultant, Advisor, Lecture Fees: Taiho, MSD, Ono, Bristol Myers Squibb, Novartis, Pfizer Inc., Chugai co., Eli Lilly and Company, Boehringer Ingelheim, Bayer AG. H. Kagamu: Financial Interests, Personal, Research Funding, Collaborative Research Fund: Boehringer Ingelheim Inc., Chugai pharm. Inc., Ono pharm. Inc.; Financial Interests, Personal, Speaker, Consultant, Advisor, Honoraria: AstraZeneca, Bristol Myers Squibb, Ono pharm., Chugai pharm. P. Feng: Non-Financial Interests, Personal, Invited Speaker: Roche, MSD, Ono, AZ; Financial Interests, Personal, Speaker, Consultant, Advisor: PharmaEssentia. B. Hughes: Financial Interests, Personal, Advisory Board: MSD, BMS, AstraZeneca, Roche, Pfizer, Takeda, Sanofi, Eisai; Financial Interests, Personal, Research Funding: Amgen. J.C. Yang: Financial Interests, Institutional, Advisory Board, My institute received fee for my role as advisory board: AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Merck KGaA, Merck Sharp & Dohme, Novartis, Pfizer, Roache/Genentech, Takeda, Yuhan Pharmaceuticals, Janssen, Puma Technology, Gilead, GSK, Dizal Pharmaceutica; Financial Interests, Personal, Coordinating PI: AstraZeneca, MSD, Dizal Pharmaceutical; Non-Financial Interests, Personal, Member: ASCO, ESMO, IASLC; Financial Interests, Personal, Research Funding: AstraZeneca, Roche; Financial Interests, Personal, Steering Committee Member: AstraZeneca, Daiichi Sankyo, Eli Lilly, Merck Sharp & Dohme, Takeda, Yuhan Pharmaceuticals, Janssen, Dizal Pharmaceutical. C.K. Lee: Financial Interests, Personal, Advisory Board: AstraZeneca, Amgen, Takeda, Pfizer, Novartis, GSK, Merck KGA, Roche, Janssen, and MSD; Financial Interests, Personal, Research Grant: AstraZeneca, Amgen, Roche, Merck KGA. P. Mitchell: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, BMS, Roche, MSD, Novartis, Pfizer ; Financial Interests, Personal, Advisory Role: Grey Wolf; Financial Interests, Personal, Coordinating PI: AstraZeneca, Amgen. Y. Tambo: Financial Interests, Personal, Speaker, Consultant, Advisor: Chugai, AstraZeneca, Taiho, MSD, Pfizer, Kyowa Kirin. E. Armenteros Monterroso: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. A. Todd: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. A. Sahasrabudhe: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. P.A. Jänne: Financial Interests, Personal, Advisory Board, Consulting fees for advice on drug development: AstraZeneca, Mirati Therapeutics, Boehringer Ingelheim, Pfizer, Roche/Genentech, Chugai Pharmaceuticals, Eli Lilly and Company, Ignyta, Takeda Oncology, Novartis, Voronoi, SFJ Pharmaceuticals, Biocartis, LOXO Oncology, PUMA, Sanofi, Transcenta, Daiichi Sa; Financial Interests, Personal, Other, Dr. Jänne is a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp: Lab Corp; Financial Interests, Personal, Research Grant: AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Takeda Oncology, PUMA, Astellas Pharmaceuticals, Daiichi Sankyo; Financial Interests, Personal, Advisory Board, Post marketing royalties from DFCI owned intellectual property on EGFR mutations licensed to Lab Corp: Lab Corp. K. Kobayashi: Financial Interests, Personal, Financially compensated role, Board Chairman: NPO North East Japan Study Group; Financial Interests, Personal, Speaker’s Bureau, Speaker Fees: AstraZeneca, Takeda Pharmaceutical Co., Daiichi Sanko Pharmaceutical Co., Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract